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Abstract 
"Theranostics" nanoparticles with superparamagnetic iron oxide core, mesoporous 
silica shell, and crown ether periphery were prepared towards drug delivery and tumor 
imaging. By the concept of nanovalve based on supramolecular gatekeeper, 
stimuli-responsive drug delivery nanosystem Fe304@Si02@meso-Si02@crown ether 
was synthesized by (i) modified solvothermal reaction; (ii) sol-gel reaction; and (iii) 
amide coupling reaction. The successful coupling of three different novel 
dibenzo-crown ethers onto the mesoporous silica shell was confirmed by 
thermogravimetric analysis and Infrared spectroscopy. In this system, the "ON/OFF" 
switching of the gatekeeper supramolecules can be controlled by pH-sensitive 
intramolecular hydrogen bonding or electrostatic interaction (such as metal chelating). 
In this work, the anti-tumor drug loading and release profiles which were studied by 
the UV/Visible absorption spectroscopy, were demonstrated by using (i) cesium 
chloride, (ii) sodium chloride, (iii) different pH values, (iv) ultrasonic wave, and (v) 
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Nanotechnology and its applications in biomedical area have been rapidly explored in 
last decades wherein their applications involve diagnosis, monitoring, and treatment 
of various diseases. In particular, a nanoparticle (NP)-based drug delivery system is 
another approach for practical biomedical applications. For therapeutic purposes, 
NPs are usually used as a drug carrier to deliver drug molecules to specific lesion sites. 
Furthermore, NPs can be modified to act as a diagnostic agent for imaging. A term 
"nanotheranostic" is coined for any nanomaterial which possesses both therapeutic 
and diagnostic p r o p e r t i e s I n contrast to bulk materials and small molecules, 
nanoscale (1-1000 nm) objects possess serendipitous properties owing to the 
nanosized effect. In particular, NPs with an average diameter less than 100 nm 
would provide better transportation efficiency and cellular u p t a k e . � 
1.1 Nanoparticle-based drug delivery 
Drug delivery is a process of administrating drug molecules to achieve a therapeutic 
effect in humans or animals, in which the product efficacy and safety inside our body 
will be enhanced. In the last decades, many research groups have been focused on 
the development of new drug delivery systems based on the advance of 
nanotechnology. It is because the nanoparticle-based drug delivery can possess 
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some advantages over the traditional one.[4] First, drug molecules can be localized 
into a NP and can be targeted to a specific lesion site of the human body by 
immobilizing nanoreceptors on the NP's surface, such as folic acid, antigens, e t c . � 
Therefore, the drug toxicity towards healthy tissues can be reduced. Besides, the 
administrated dosages of the drug can be minimized since the drug can be 
encapsulated inside the nanoparticles, also the degradation of drug can be reduced. 
Overall, the drug efficacy inside human body can be enhanced. 
As reported in the literature, an ideal drug delivery system requires two essential 
components.[3’5] They are the targeting ability of the carriers and the controlled 
release profile of the drug from the carrier. In order to achieve a good targeting 
delivery system and to minimize undesired side effects and improve the drug 
efficiency, the carrier can be modified by targeting agent such as folic acid. Also, 
the targeting properties can be adjusted by the nature of the material, such as magnetic 
targeting by magnetic nanoparticles, or the size of nanoparticles, since a relatively 
large (>20 nm) nano/microspheres will be quickly up-taken by the reticuloendothelial 
system (RES) and hence targeted delivery of these nano/microspheres to liver, spleen, 
lymph nodes, and bone marrow can be achieved. 
As an ideal drug delivery system, the carrier material should be biocompatible. 
For example, iron oxide and silica are non-cytotoxic. Also, the system loading 
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amount of the desired drug molecules should be high and should be zero premature 
release before reaching to the target site, in order to minimize undesirable side effects 
and dosage of drug administration. 
Recently, NPs have been prepared by different materials such as metal/metal 
oxide, dendrimers, liposomes, polymer vesicles, micellar nanoparticles, etc, from 
which their structures and sizes of the NP can be controlled•� Also, the shape of the 
particles can be sphere, prism, pyramid, cubic, wires, etc. Moreover, the architecture 
of NPs can be hollow, core/shell, flower, dumbbell, etc. Besides, NPs can be ftirther 
functionalized by different bio material such as drug, DNA, protein, fluorescence dye, 
etc, such that a multi-functional NP can be prepared for therapeutic purpose.[6� One 
example is a lipid-polymer hybrid NP as drug carrier. 
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Figure 1. Schematic diagram of lipid-polymer hybrid nanoparticle with hydrophobic 
PLGA (polylactic-co-glycolic add).[7� 
A lipid-polymer hybrid core/shell nanoparticle is shown in Figure l.[7� In this 
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nanosystem, the biodegradable hydrophobic polymeric core and a biocompatible 
hydrophilic shell are applied, which evaded the recognition by immune system 
components and increase particle systemic circulation half-life. Also, a lipid 
monolayer is applied at the interface between the hydrophobic core and the 
hydrophilic shell in order to prevent the leakage of trapped substrates from the NPs. 
Recently, magnetic iron oxide NPs are one of the attractive materials for 
NP-based drug delivery and it can be served as magnetic resonance imaging (MRI) 
contrast agent for diagnosis simultaneously.^ Currently, silica-based core/shell iron 
oxide NPs are extensively investigated. Figure 2 represents a nanocarrier which 
involves iron oxide nanocrystals encapsulated by mesoporous silica.[9� In this 
system, magnetic iron oxide NPs can act as MRI contrast agent for diagnosis, and 
provide magnetic targeting properties for drug transportation. Also, folic 
acid-targeting ligands have been immobilized onto the surface of the NP, providing a 
specific targeting effect towards lesion tissues, e.g., cancers. Moreover, porous 
silica shell with high surface area has been coated onto the magnetic core to allow 
drug storage. Also, silica shell provides better functionalization platform for further 
surface modification and a protection to iron oxide NPs. 
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Figure 2. Schematic illustration of a multi-functional nanoparticle which consists of 
iron oxide nanocrystals encapsulated by mesoporous silica with phosphonate coating 
and folic acid targeting ligand.[9] • 
1.2 Magnetic nanoparticle 
Magnetic NPs with superparamagnetism and inherently biocompatibilities have been 
shown promises in the biomedical area, especially in MRI and hyperthermia 
techniques for monitoring cancer and treatment.[丨，�]In these cases, magnetic NPs act 
as a negative contrast enhancement agent for MRI monitoring, and as a heat generator 
under an alternating magnetic field in hyperthermia treatment. In particular, the use 
of magnetic NPs as a part of drug delivery carrier is also introduced recently, such as 
the mesoporous/hollow iron oxide NPs,[io] and silica based core/shell iron oxide 
NPs.[9] Furthermore, they can be used for immunoassay, detoxification of biological 
fluids, and cell separation, which strongly depends on the surface functionalization of 
the NPs. [i’2] 
Generally, magnetic NPs can be ferro-magnetic, ferri-magnetic and 
'V 
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superparamagnetic.[丨丨]However, NPs used in biomedical applications should behave 
non-magnetically when an externally applied magnetic field is removed, in order to 
prevent the magnetic agglomeration.[3’ 丨2] Hence, superparamagnetic NPs are more 
attractive for nanotheranostic research. Besides, surface modifications are another 
important issue for the development of a nanosystem, as it can provide additional 
functionalities in biomedical applications. Typically, magnetic NPs are investigated 
in various forms such as iron oxide-based NPs, cobalt-based NPs and iron-based NPs. 
The cobalt-based NPs generally show a strong magnetization property but the toxicity 
of these NPs is a major concern for biomedical applications. The pure iron-based 
NPs are other common magnetic NPs. However the high sensitivity towards air 
auto-oxidation is a major disadvantage for biomedical applications. 
1.3 Iron oxide nanopartide 
Iron oxide nanoparticles, such as superparamagnetic iron oxides (SPIO) and 
ultrasmall superparamagnetic iron oxides (USPIO)，have been served as MRI contrast 
agents. They are composed of nanocrystalline magnetite (Fe304) or maghemite 
(丫-Fe203) and generally with polymeric coating. Moreover, most of the iron oxide 
NPs are biocompatible. Some of them are commercially available such as Feridex, 
Endorem, etc, which has been approved by FDA for medical usqP^ Nowadays, 
SPIO can be synthesized by numerous chemical methods, such as microemulsions, 
6 
sol-gel syntheses, sonochemical reactions, hydrothermal reactions and coprecipitation. 
1.3.1 Coprecipitation 
Coprecipitation is by far the simplest and efficient method for preparation of magnetic 
iron oxide NPs. It can be easily prepared by mixing the 1:2 stoichiometric amount 
of the ferrous and ferric salts in aqueous medium, in which a large amount of the NPs 
can be synthesized. The chemical equation of the iron oxide NPs is shown as 
below:[i4’i5] 
Fe2+ + 2Fe3+ + 80H_ FesC^ + 4H2O 
In principle, the size of the particles can be controlled by varying the pH of 
solution, ionic strength, temperature, nature of salts, concentration ratio of the ferrous 
and ferric salts or the addition of chelating agents (such as carboxylate or citrates 
ions). However, the control of the particles size distribution is somewhat limited in 
this process. Due to this limitation, other synthetic methods with constrained 
environments are being investigated to prepare monodispersed nanoparticles. 
1.3.2 Hydrothermal reaction 
Hydrothermal synthesis of iron oxide NPs has been already reported in the 
l i t e r a t u r e . [ i 4 ] In this process, the reactions are performed in aqueous media in an 
autoclave with high pressure and temperature. As described in the literature, the size 
and the shape of NPs could be controlled by manipulating the reaction conditions, 
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which include temperature, pressure, time, and solvent. In principle, the particle size 
of NP is controlled by the rate of nucleation and grain growth. In general, at higher 
temperature with other conditions kept constant, the nucleation will be faster, and 
hence the size of the particles will be decreased. On the other hand, with prolonging 
reaction time, the grain growth will be enhanced and result in a larger particle size. 
1.3.3 Sol-gel reaction 
Furthermore, NPs can be prepared by sol-gel reactions, in which the process involves 
the hydroxylation and condensation of the precursors in solution, and followed by 
further condensation and inorganic polymerization in a wet gel. In this process, the 
architecture of the NPs is greatly dependable on the solvent, temperature, 
concentration of the precursors, pH, etc. 
The solvent used in this process can be polyols (such as polyethylene glycol), 
which is known as a polyol process. In this process, polyols provide a wide range of 
optimal temperatures according to their boiling points and act as reducing agent and 
stabilizers to control the size and architecture of NPs. Moreover, the obtained NPs 
in this process should possess a higher crystallinity and higher magnetization over the 
aqueous one. 
1.3.4 Solvothermal reaction 
Solvothermal reaction is similar to the hydrothermal p r o c e s s ， " 6] wherein it is also 
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performed at high pressure and temperature by conducting in a stainless steel 
autoclave. One of the main differences between the two processes is the media of 
the reaction. In solvothermal reaction, the solution is not aqueous, and can be 
organic solvent, polyol, etc. Similarly, the size and architecture of the NPs are 
dependable on the temperature, pressure, reaction time, solvent, concentration of the 
precursors, pH, etc. 
1.3.5 Architecture of iron oxide nanoparticles as drug carrier 
In the development of NPs for drug delivery applications, the NPs can be either 
conjugated with the drug or possessed porous channels for drug storage. In the last 
decades, porous silica NP, MCM-41, has been reported as drug containers due to the 
well-developed synthetic and surface functionalization methods. Recently, 
core/shell NPs with magnetic iron oxide NPs as the core, and mesoporous silica as the 
coating shell, have been r e p o r t e d / ! ？ ] in which the overall core/shell NPs can gain 
some advantages over the MCM-41. First, the magnetic core can serve as MRI 
contrast agent. Also, the NPs can be manipulated by external magnetic field, which 
provide additional targeting ability for drug transportation. Mesoporous silica shell 
with different nanopore size can be obtained for storage of different drug molecules. 
Hence, the use of this theranostic NP becomes one of the strategies for drug delivery 
application. 
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1.4 Supramolecular chemistry involved in controlled release drug delivery 
system 
As mentioned previously, the controlled formulation is another important parameter 
for drug delivery system. In the past, the traditional methods for drug delivery, such 
as injections, tablets and sprays, are very inefficient for certain drugs and require 
multiple administrations to maintain the concentration of the drug in the blood at a 
therapeutically effective level for reasonable periods of time.[i8] In order to control 
the drug level inside the body, many novel smart nanocontainers have been reported 
by using different techniques, such as the use of biodegradable polymer, switchable 
molecular machine, environmental sensitive biomaterial, etc.[i9] In the last decades, 
drug delivery based on supramolecular chemistry has been successfully demonstrated 
by introducing a supramolecular "nanogate" onto the surface of the NPs, and 
controlling the release of drug by external stimuli, such as light, pH, ultrasound, 
enzyme, temperature, etc. In Figure 3, it shows an example of light-responsive 
supramolecular chemistry gated drug delivery system.[6� 
1 0 
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Figure 3. Supramolecular gatekeeping of nanochannels by photo-dimerization of 
coumarins coupled onto the surface of mesoporous silica materials and schematic 
diagram of ON/OFF switching of molecular gates under external stimuli.[6] 
In principle, supramolecular chemistry is defined as "the chemistry of molecular 
assemblies and of the intermolecular bond" by Jean-Marie Lehn.po] In other words, 
it is related to the chemistry of noncovalent interactions, such as hydrogen bonding, 
electrostatic interaction, hydrophobic effect, etc, in which the relatively weak 
noncovalent interaction can be easily varied or undergone conformational changes by 
external environment. Based on this characteristic, the idea of molecular devices is 
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first introduced in 1970’s.[20] According to Lehn's d e f i n i t i o n , a molecular device 
is defined as structurally organized and functionally integrated chemical systems in 
supramolecular architectures, in which the component can be photo-, electro-, iono-， 
magneto, thermo-, mechano-，or chemo-active, depending on whether the component 
governs by the photons, electrons or ions, respond to magnetic field or to heat, 
undergo changes in mechanical properties or perform a chemical reaction. 
Some molecular devices based on supramolecular chemistry are shown in Figure 
4.[22� They include stilbene cis-trans isomerization, diarylethene electrocyclization, 
and azobenzene cis-trans isomerization. Moreover, the molecular switching 
stimulated by a molecular recognition is shown in Figure 5.[23� Also, pH-responsive 
rotaxane-based molecular switching is described in Figure 6.[24� 
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Figure 4. Photo-responsive molecular devices, a) stilbene cis-trans isomeriztion, b) 
diarylethene electrocyclization, and c) azobenzene cis-trans isomerization. 
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Figure 5. Molecular switches stimulated by molecular recognition, eT: energy 
transfer. 
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Figure 6. Rotaxane-based pH-responsive switching molecular device. 
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1.5 Nanovalve 
By using different responsive interlocked molecules, supramolecular gatekeepers 
(valves) with different sensitivities towards external stimuli can be established for 
biomedical applications, in order to control the substrate/drug release profile based on 
a reservoir material. In most cases, "pseudorotaxane" type nanovalves which 
involve macrocycles as gatekeepers, have been recently investigatedJ^^'^^^ Generally, 
the actuation of nanovalves can be controlled by different stimuli such as pH, light, 
redox, heat, oscillating magnetic field, competitive binding, etc, to facilitate a 
controlled substrate/drug release. An example is shown in Figure 7.[26] The 
nanovalves which are based on cucurbituril (CB)-bisammonium supramolecular 
recognition, could be dissociated by an oscillating magnetic field, followed by a 
release of the trapped substrates in a porous silica NP. However, the macrocyclic CB 
component of the nanovalves would also be released at the same moment of the 
drug/substrate, leading to undesirable side effects. 
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Figure 7. Schematic diagram and a selected example of "pseudorotaxane" type 
nanovalves based on cucurbituril (CB)-bisammonium supramolecular recognition. [26] 
Besides the "pseudorotaxane" type nanovalves, "rotaxane" type nanovalves have 
been r e p o r t e d ^ s ] An example is shown in Figure 8. A bistable [2]rotaxane 
which is based on cyclobisparaquat-/?-phenylene (CBPQT/"^ tetracationic macrocycle, 
tetrathiafulvalene (TTF)，and dioxynaphthalene (DNP), was employed to construct the 
nanovalve on the surface of porous silica NP. Similarly, the substrate can be easily 
loaded into the nanopores by diffusion under different concentration gradients. The 
release of substrate can be triggered by a reduction through ascorbic acid so that 
macrocyclic rings on the threads would be switched to another station and away from 
the pores. This process did not destroy the architecture of nanovalve and hence the 
undesirable effect came from the release of macrocyclic can be reduced, 
1 6 
t f # f i t 
S 1 , 1 bistable [2|rotaxane 〔 藝 , 1 
！ ！ 1 / 1 1 i � 
trapped substrate • ^ ^ ^ • 
：•!； i o o . . h \ addition ‘ \ released substrate 
i* \ \ ：a® \ of ascorbic acid \ 
y 7 \ ) 
Porous silica NP 
M T • 
4 PFr 
A bistable [2]rotaxane 
Figure 8. Switchable bistable [2]rotaxane-type n a n o v a l v e . [ 2 7 ] 
1.6 Aim of project 
It has been demonstrated that interlocked molecular switches are useful prototypes for 
the construction of nanovalves for controlled substrate release. However, the use of 
crown ethers as the sole molecular component of nanovalve was not reported. In 
this project, a series of nanovalves has been developed by using novel switchable 
dibenzo-crown ethers for controlled release system based on novel magnetic porous 
NPs. The NPs are magnetic responsive iron oxide NP, and mesoporous silica shell 
for drug storage, resulting a series of novel crown ether-based, theranostic NP systems. 
These NP systems as well as their molecular components have been characterized by 
various spectroscopic methods. The cytotoxicity and MRI response of these systems 
have been evaluated. Furthermore, systematic drug release profiles of these NP 
1 7 
M m l nanostructures have also determined, rendering them useful theranostic nanomaterials. 
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Chapter 2 
Stimuli-Responsive Drug Delivery Nanosystems Based 
on Fe304@Si02@mesoSi02@crown ether 
Nanoparticles 
2.1 Background 
In this project, a series of dibenzo-crown ethers was designed to act as the 
gate-keepers of nanovalves with the aim for NP-based drug delivery. Crown ether is 
a macrocyclic poly ether compound with strong binding affinity towards various 
cations._ Novel dibenzo-crown ethers (Figure 9) which consist of two carboxylic 
groups, could be coupled to the amine surface of a hexagonal pore of mesoporous 
silica NPs, forming amide linkages. Also, preorganized crown ethers possess 
electrostatic interactions towards different cations, allowing the possibility of using 
different metal ions act as a capping agent. In this nanosystem (Figure 10), 
dibenzo-crown ethers were coupled onto the pores entry of the NPs to control the 
release of substrates. The capping agent can be either metal ions or simply a proton. 
In the presence of capping agent, drug molecules would not be diffused freely, and 
escaped from the pores of NPs. However, it is expected that the release of drug 
molecules can be triggered by ultrasonic waves. An ultrasonic device could be 
clinically available in many hospitals wherein ultrasonic waves are routinely used for 
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non-invasive diagnosis. Also, the capping agent (Na+ or H+) is used in the 
nanovalves to mimic the environments of blood and slightly acidic cancer lesion site. 
Therefore, the leakage of drug from the NPs in the body can be minimized due to the 
dissolution of capping agent before cellular uptake. 
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Figure 9. a ) The molecular structure of the novel dibenzo-crown ethers la-c and b) 
schematic diagram of a hexagonal pore of amine-functionalized mesoporous silica 
NP. 
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Figure 10. Schematic diagram of dibenzo-crown ethers as nanovalves for controlled 
release of a substrate, e.g., doxorubicin hydrochloride salt (DOX). 
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2.2 Synthesis of dibenzo-crown ethers 
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Figure 11. Synthetic scheme of a series of novel dibenzo-crown ethers la-c. 
The synthetic scheme of a series of novel dibenzo-crown ethers la-c is shown in 
Figure 11. First, the 2,6-dihydroxylbenzoic acid was protected by an acetal group ‘ 
with acetone in the presence of thioyl chloride and a catalytic amount of 
4-dimethylaminopyridine (DMAP), giving the acetal 2 with 45% yieldJ^^^ Then, 
acetal 2 was reacted with either triethylene or tetraethylene glycol ditosylate under a 
Williamson ether synthetic protocol to give polyethers 3a or 3b in 53% or 35% yield, 
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respectively. Afterwards, the acetal groups of the polyethers 3a-b were separately 
deprotected by using sodium methoxide in methanol to give diester 4a or 4b, 
respectively. The reaction yields of 4a and 4b were 94% and 95%, respectively. 
Subsequently, the diesters 4a-b were cyclized with cesium cation-templated reaction 
in the presence of either triethylene or tetraethylene glycol ditosylate under reflux in 4 
days. The cyclization reactions gave the dibenzo-crown ether esters 5a-c in 19%, 
37% and 35% yield, respectively. Finally, the dibenzo-crown ether esters 5a-c were 
treated with sodium hydroxide under reflux to obtain the desired dibenzo-crown 
ethers la-c in 64%, 76% and 71% yield, respectively. 
2.3 Synthetic method of functionalized nanoparticles 
Core/shell Fe304@Si02@meso-Si02 NPs were prepared by two processes, a 
modified hydrothermal reaction and a sol-gel reaction. Figure 12 shows the 
preparation of core/shell Fe304@Si02@meso-Si02 NPs. First, high magnetization, 
superparamagnetic Fe304 NPs with an average diameter of 130 nm were prepared 
according to the literature p r o c e d u r e s . [ 3 � ] The NPs were synthesized by dissolving 
ferric chloride in a mixture of diethylene glycol and ethylene glycol, sodium acetate 
and polyacrylate, following by a heat treatment at 200 °C in an autoclave. 
Noticeably, the size of the Fe304 NPs can be tunable by changing the ratios of 
diethylene glycol and ethylene glycol. Then, the as-synthesized Fe304 NPs 
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underwent a sol-gel reaction to form a silica coating with an approximate thickness of 
5 nm. The thickness of the silica coating can be easily adjusted by the amount of 
tetraethyl orthosilicate (TEOS) added to the NP solutionPi] j h i s thin layer of silica 
of the Fe304@Si02 NPs act as a template for a smooth coating of mesoporous silica. 
Poly(vinylpyrrolidone) (PVP) was dispersed into the Fe304@Si02 NP solution with 
sonication for mesoporous silica coating, to minimize the interaction between the 
slightly negatively charged silica coating and the positively charged surfactant, cetyl 
trimethylammonium bromide (CTAB). CTAB, which also act as a 
structure-directing agent, was added to the NP mixture for porous Si02 formation. 
CTAB would form hexagonal self-assemblies of micelle during the hydrolysis of 
silica sources.[32] According to the literature, the pore diameters of the mesoporous 
Si02 can be controlled by changing the ratios of the silica source and the 
structure-directing agent.[33] Finally, the surfactant (CTAB) trapped inside the 
Fe304@Si02@meso(CTAB)-Si02 NPs can be easily removed by either 
ion-exchange method with ammonium nitrate or a solvent, such as acetone, water, etc, 
yielding the Fe304@Si02@meso-Si02 NPs. Subsequently, the obtained NPs can be 
further functionalized effectively. 
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Figure 12. Schematic diagram of the preparation of the Fe304@Si02@meso-Si02 
NPs. 
The surface of Fe304@Si02@meso(CTAB)-Si02 NPs were then functionalized, 
as shown in Figure 13，by 3-aminopropyltriethoxysilane (APTES) with mechanical 
stirring for 24 hrs. The reaction was quenched after a 24-hour reaction. The 
surface thickness of the nanostructure will be affected for prolonged reaction time. 
Then, the amine-flinctionalized mesoporous NPs Fe304@Si02@meso(CTAB)-Si02 
were reacted by the designed dibenzo-crown ethers la-c in the presence of the 
coupling agents, A^-hydroxysuccinimide (NHS) and N, A^'-dicyclohexylcarbodiimide 
(DCC). Finally, CTAB surfactant were removed by several washing steps with 
N, A^-dimethy Iformamide (DMF) and water, yielding the desired 
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Figure 13. Schematic diagram of the preparation of 
Fe304@Si02@meso-Si02@crown ether(a-c) and Fe304@Si02@meso-Si02-NH2 
NPs. 
2.4 Characterization of dibenzo-crown ethers 
2.4.1 Nuclear magnetic resonance (NMR) spectroscopy 
The stacked ^H NMR spectra of dibenzo-crown ethers la-c are shown in Figure 14. 
The proton signals at S 121 ppm and <5 6.55 ppm can be attributed to the aryl protons 
(Ar-//) of dibenzo-crown ethers la-c. In addition, the ethylene glycol protons 
{CH2O-) resonate as multiplets in the region ranging from <5 3.5 to 4.2 ppm. These 
results support that desired dibenzo-crown ethers la-c were successfully synthesized. 
Also, stacked '^C NMR spectra of dibenzo-crown ethers la-c are shown in 
Figure 15. The carbon signals at d 171 ppm can be attributed to the carbonyl carbon. 
In addition, aromatic (Ar) carbons resonate as four signals at <5 105, 113, 131, 157 
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ppm. Also, the ethylene glycol carbons (CH2O-) resonate as multiple signals in the 
region ranging from d 69 to 72 ppm. These results support that the desired 
dibenzo-crown ethers la-c were successfully synthesized. 
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Figure 14. Stacked ^H NMR (CDCI3, 297K) spectra of dibenzo-crown ethers, a) la, b) 
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Figure 15. Stacked ^^ C NMR spectra (CDCI3, 297K) of dibenzo-crown ethers, a) la , b) 
lb , and c) Ic. *: solvent residue. 
2.4.2 Mass spectrometry (MS) 
The dibenzo-crown ethers la-c were also analyzed by using high resolution 
2 7 
J. 
electrospray ionization mass spectrometry (ESI-MS). A singly charged molecular 
ion base peak (w/z) of 559.1786, 603.2038, 647.2311 were observed, which is 
corresponded to the dibenzo-crown ethers l a - c � N a + molecular ion with theoretical 
values of 559.1786, 603.2048，647.2310, respectively. The ESI-MS results reveal 
that the synthesis of dibenzo-crown ethers la-c through the synthetic scheme (Figure 
11) is success. 
2.4.3 Infrared (IR) spectroscopy 
A series of dibenzo-crown ethers la-c were also characterized by IR spectroscopy, 
confirming the presence of IR absorptions corresponding to 0 - H stretching and C=0 
stretching of carboxylic acid dimer. In principle, the carbonyl stretching absorption 
is observed at about 1760-1730 cm"' for the monomer and 1730-1700 cm"' for the 
dimer. As observed in the IR spectra, the C=0 stretching absorption peak is 
observed near 1700 cm'' for both dibenzo-crown ether Ib-c, indicating the presence 
of the dimer. Also, the 0 - H stretching is observed at about 2550 cm'' for both cases, 
which is the characteristic absorption peak of 0 - H stretching due to the hydrogen 
bonding present in the dimer. However, C=0 stretching absorption peak is found in 
1730 cm-i and the 0 - H stretching at about 2550 cm"' is relatively weak in the case of 
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Figure 16. IR spectra of dibenzo-crown ethers, a) la , b) lb , and c) Ic, in KBr pellet. 
2.5 Characterization of nanoparticles 
2.5.1 Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) was performed for analysis the 
morphologies of the NPs. It is a powerful tool for investigation of the internal 
structure of the NPs. The contrast of the patterns/structures in the TEM images are 
greatly depend on the nature of the NPs and the sample grid, e.g., copper grid. 
Monodisperesed Fe304 NPs with an average diameter 130 nm were successfully 
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synthesized by changing the ratio of diethylene glycol and ethylene glycol with other 
conditions kept constant and the TEM image is shown in Figure 17. Afterward, the 
monodisperesed Fe304 NPs underwent a sol-gel reaction in the presence of TEOS and 
ammonia solution in ethanol, to obtain a core/shell nanostructure. The core part was 
magnetic Fe304 NPs and the shell part is SiOz- As observed in the TEM images of 
core/shell NPs Fe304@Si02 (Figure 18), the size of the FesOd magnetic core remains 
unchanged during the sol-gel process. Also, a thin layer of silica coating with 5 nm 
thickness is observed (Figure 18). 
Figure 17. TEM images of Fe304 NPs with an average diameter of 130 nm. 
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Figure 18. TEM images of Fe304@Si02 core/shell NPs. 
With the support of a thin layer of silica, a smooth coating of mesoporous silica 
was obtained to yield the Fe304@Si02@meso(CTAB)-Si02 NPs. As shown in the 
TEM images (Figure 19), the nanopores cannot be clearly observed due to the 
presence of surfactant (CTAB) in the pores. The size of the mesoporous NPs were 
determined with an average diameter of 250 nm. The thickness of the mesoporous 
silica coating was found to be 60 nm. Also, some of tiny silica NPs are inevitably 
present due to the incompletely washing of NPs with water under external magnetic 
field. The tiny silica NPs can be removed after the functionalization of NPs to 
prevent the undesired removal of CTAB surfactant during the washing process. 
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Afterwards, mesoporous NPs (Fe304@Si02@meso(CTAB)-Si02) were 
functionalized by APTES to give the Fe304@Si02@meso(CTAB)-Si02-NH2 NPs. 
Figure 20 reveals the TEM images of the Fe304@Si02@meso(CTAB)-Si02-NH2 
NPs. The particles size is somewhat increased slightly. A magnified TEM image 
(Figure 20A) shows clearly the mesopores in the silica layer of the particle. 
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Figure 19. TEM image of mesoporous NPs (Fe304@Si02@meso(CTAB)-Si02 
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Figure 20. TEM images of mesoporous NPs Fe304@Si02@meso(CTAB)-Si02-NH2. 
Finally, mesoporous NPs Fe304@Si02@meso(CTAB)-Si02-NH2 underwent 
first, the coupling reaction with dibenzo-crown ethers la-c in the presence of NHS 
and DCC and second, the CTAB removal, giving the desired NPs 
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Fe304@Si02@meso-Si02@crown ethers(a-c) with an average diameter of 250 nm. 
From the TEM images (Figures 21-23), the core/shell nanostructures had not 
jeopardized by the coupling and surfactant removal reactions. The mesopores of the 
silica shell layer can be clearly observed in their magnified TEM images (Figures 21b, 
22b, 23b). 
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Figure 21. TEM images of the Fe304@Si02@meso-Si02@crown ether(a). 
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Figure 22.TEM images of the Fe304@Si02@meso-Si02@crown ether(b). 
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Figure 23.TEM images of the Fe304@Si02@meso-Si02@crown ether(c). 
2.5.2 Energy-dispersive X-ray (EDX) spectroscopy 
EDX which is equipped with the TEM instrument, is a useful technique for elemental 
analysis of NPs. With the supporting platform of TEM, the elemental compositions 
of NP at different regions can be easily determined. First, the thin layer SiCh coating 
of the Fe304@Si02 NPs was characterized by EDX and scanning transmission 
electron microscope (STEM) to ensure the formation of silica coating. In the EDX 
spectrum, corresponding signal (4.5% at ca. 1.8 keV) of silica was observed, 
indicating that silica is present in the NPs after sol-gel reaction. The EDX signals of 
copper and carbon are inevitably observed because of the use of carbon-coated copper 
grid support for TEM analysis. Afterwards, STEM analysis was carried out to scan 
across a Fe304@Si02 NP (Figure 25a). An overall EDX spectrum (Figure 25b) and 
the EDX spectra of Fe (Figure 25c) and Si (Figure 25d) elements of a NP were 
obtained. The EDX spectrum of silica with respect to the regions of NPs shows that 
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the surface of NPs were coated with a layer of silica, indicating that the silica coating 
was success with a thickness of 5 nm compared to the iron oxide core. 
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Figure 24. EDX spectrum of Fe304@Si02 core/shell NPs. 
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Figure 25. STEM scanning profile of Fe304@Si02 a) and corresponding EDX spectra 
b) with respect to c) Fe and d) Si elements. 
In the EDX spectrum of Fe304@Si02@meso(CTAB)-Si02-NH2 NPs (Figure 
26), the emission peak of silica is observed and the relative peak intensity ratio of Si 
to Fe is greatly enhanced, indicating that the composition of Si02 contributed to the 
NPs is increased, when compared to the Fe304@Si02 NPs. This is because there is 
a 60 nm of mesoporous silica coating in the Fe304@Si02@meso(CTAB)-Si02-NH2 
NPs, which strongly agreed with the TEM analysis mentioned previously. • 
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Figure 26. EDX spectrum of Fe304@Si02@meso-Si02-NH2. 
The EDX spectra of mesoporous NPs after the coupling of dibenzo-crown ethers 
are shown in Figures 27-29. The emission peaks of silica and iron are observed, 
indicating that the NPs also consist of silica and iron. The relative peak intensity 
ratio of Si to Fe does not show significantly differences between amine functionalized 
NPs and crown ether-functionalized NPs, indicating the composition of NPs are not 
varied so much after the coupling with organic components. 
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Figure 27. EDX spectrum of the Fe304@Si02@meso-Si02@crown ether(a). 
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Figure 28. EDX spectrum of the Fe304@Si02@meso-Si02@crown ether(b). 
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Figure 29. EDX spectrum of the Fe304@Si02@meso-Si02@crown ether(c). 
2.5.3 IR spectroscopy 
The success of coupling between the dibenzo-crown ethers la-c and 
Fe304@Si02@meso-Si02-NH2 NPs is proven by IR spectroscopic characterization, 
confirming the presence of IR absorptions corresponding to N-H stretching, C=0 
stretching, and N-H bending. However, in the case of surface functionalization of 
NPs, the signal of the corresponding stretching or bending is significantly weakened. 
As observed in the IR spectrum shown in Figure 30，the N-H stretching and N-H 
bending are observed in all cases with different intensities, indicating that N-H bond 
is present either in amine group or amide group. In order to distinguish the amide 
and amine, the presence of C=0 stretching is an important evidence. In the cases of 
dibenzo-crown ethers, C=0 stretching at 1628 cm'^ is observed and the relative ratio 
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compared to the N-H bending at 1548 cm'^ is increased. Based on this observation, 
it is reasonable to believe that the coupling between the dibenzo-crown ethers and the 
amine-functionalized NPs is successful. 
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Figure 30. IR spectra of functionalized NPs, a) Fe304@Si02@meso-Si02@crown 
ether(a), b) Fe304@Si02@meso-Si02@crown ether(b), c) 
Fe304@Si02@meso-Si02@crown ether(c), and d) Fe304@Si02@meso-Si02-NH2, 
in KBr pellet. 
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2.5.4 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) provides the information on changes in weight of 
NPs with increasing temperature. It usually gives evidences of the % organic 
fraction in a sample. The TGA spectra of the mesoporous NPs with CTAB and 
functionalized mesoporous NPs are shown in Figures 31-35. In the TGA spectra, 
two major weight loss events in the temperature range of 150 to 400 °C and 450 to 
800 °C are observed. According to the l i t e r a t u r e , [ 3 4 ] the weight loss at 1.50 to 400 °C 
is corresponding to the thermal decomposition of NPs' surface organic moiety and/or 
surfactant molecules, while the weight loss at 450 to 800 °C is due to dehydroxylation 
of the silicate networks on mesoporous silica materials. Hence, the differences 
between the weight losses at 150 to 450 were important indication for the changes 
in functionality of the mesoporous silica shell. As shown in the spectra (Figure 32-35), 
the percentage weight loss after coupling with dibenzo-crown ethers la-c is ranging 
from 7.7-7.9%, while the percentage weight loss before coupling is only 5.6%. 
From this result, an additional 2% of organic fractions were found after the crown 
ether coupling reaction. The weight losses onto the surface of NPs are regarded 
reasonable as the weight loss of mesoporous NPs with CTAB was found 14.1% 
(Figure 31). Therefore, this result indicated that the coupling of dibenzo-crown 
ethers la-c to the amine functionalized NPs (Fe304@Si02@meso(CTAB)-Si02-NH2) 
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were successful. 
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Figure 35. TGA spectrum of Fe304@Si02@meso-Si02@crowii ether(c). 
2.5.5 Nitrogen adsorption/desorption isotherms 
Nitrogen adsorption/desorption isotherms were performed for determining the specific 
surface areas and pore sizes of Fe304@Si02@meso-Si02-NH2 NPs. The pore size 
distribution curve of these NPs (Figure 36) indicates that a layer of mesoporous 
coating with average diameter of 3.2 nm pores was obtained. Also, the BET surface 
area of NPs was determined as 404.6593 士 1.1189 m^/g. The relatively high surface 















0 . 0 0 - 1 ~ ~ I I j = T = I ~ I ~ I I ~ ~ I I I ‘ I ‘ I ‘ 
2 4 6 8 10 12 14 16 18 20 
Pore diameter / nm 
Figure 36. Pore size distribution curve of Fe304@Si02@meso-Si02-NH2NPs. 
2.6 Biological study of functionalized nanoparticles 
2.6.1 Cytotoxicity study 
To aim as drug delivery systems, biocompatibility of the NPs should be evaluated. 
In principle, NPs, which act as drug delivery carrier, should be noncytotoxic and can 
be preliminary estimated by determining its cytotoxicity through 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In 
MTT assay, the relative cell viability (%) for NPs related to control well towards L929 
normal cells, which is a murine aneuploid fibrosarcoma cell line, was determined and 
shown in Table 1. In all cases, the viability of L929 cells was not affected by 
exposure to various concentrations (12.5 to 100 |ig Fe/mL) of NPs for 24 hrs. These 
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results suggest that the four different NPs did not posses acute toxicity in L929 cells. 
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@crown ether(a) 
F e 3 0 4 @ S i 0 2 @ i n e s o - S i 0 2 , 
u u 100% 104 士 10/0 102 士 2% 102 士 6o/o 106 土 5% 
@crowii ether(b) 
Fe3O .@SiO.@mes0-S iO.贈％ 丨 � 士 �％ 丨⑴ 士 2% 102 士 2% 106 士 5 � / � 
@crown ether(c) 
Table 1. Viability of L929 cells exposed to NPs for 24 hrs at various Fe concentrations 
(n=3). 
2.6.2 Cell adhesion study 
The effect of cell adhesion towards L929 cell by NPs was also studied, wherein 
correct cellular adhesion was important for maintaining cellular structure of cells. In 
cell adhesion study, MTT essay was performed to determine the cell viability. In 
principle, cell viability was correlated to the effect of NPs towards cell adhesion, 
wherein high cell viability represents that NPs do not possess significant effect 
towards the cell adhesion. As shown in Table 2, L929 cell adhesion was not affected 
by exposure to various concentrations (12.5 to 100 |ig Fe/mL) of NPs after 4 hrs 
incubation. 
4 6 
Fe concentration (p,g/mL) 
Nanoparticle ‘ 
0 1 2 ^ 2 5 50 100 
F e 3 0 4 @ S i 0 2 @ m e s o - ^^ 
u 1 0 0 % 9 7 士 7 % 9 3 士 3o/o 9 7 士 3o/o 104 士 6o/o 
S i O z - N H z 
F e 3 0 4 @ S i 0 2 @ m e s o - S i 0 2 
u � 1 0 0 % 9 6 ± l o / o 9 9 土 2o/o 1 0 4 土 40/0 106 士 4o/o 
@crown ether(a) 
F e 3 0 4 @ S i 0 2 @ i n e s o - S i 0 2 
� 1 0 0 % 9 0 士 20/0 91 士 3o/o 9 4 士 40/0 9 7 士 2o/o 
@crown ether(b) 
F e 3 0 4 @ S i 0 2 @ m e s o - S i 0 2 , 
^ 1 0 0 % 9 3 ±30 /0 9 7 士 50/0 1 0 4 ± 6 % 112 士 IQo/o 
@crown ether(c) 
Table 2. Viability of L929 cells exposed to NPs for 4 hrs at various Fe concentrations 
(n=3). 
2.6.3 Cell proliferation study 
The effect of NPs on cell proliferation for L929 cells was determined. In other 
words, the effect of NPs on cell growth was investigated. Similarly, the effect can be 
estimated by MTT essay and the results of cell proliferation study towards NPs are 
shown in Figures 37-40. In principle, high cell viability represents that the NPs did 
not show any significant inhibition towards cell growth. In the cases of 
Fe304@Si02@meso-Si02-NH2, Fe304@Si02@meso-Si02@crown ether(b) and 
Fe304@Si02@meso-Si02@crown ether(c) NPs, they do not show any effect on 
L929 cell proliferation at low concentrations (12.5 to 50 昭 Fe/mL)，while slightly 
inhibition on cell proliferation after 72 hrs incubation was found at 100 \ig Fe/mL. 
However, there was a slightly inhibition on cell proliferation towards L929 cell by 
Fe304@Si02@meso-Si02@crown ether(a) NPs even at lower concentration after 72 
47 
hrs incubation. Hence, it is more likely that Fe304@Si02@meso-Si02@crown 
ether(a) NPs were less biocompatible towards L929 cell when compared with other 
NPs. 
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Figure 37. Viability of L929 cells exposed to Fe304@Si02@meso-Si02-NH2 NPs at 
various iron concentrations (n=3). 
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Figure 38. Viability of L929 cells exposed to Fe304@Si02@meso-Si02@crown 
ether(a) NPs at various iron concentrations (n=3). 
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Figure 39. Viability of L929 cells exposed to Fe304@Si02@meso-Si02@crown 
ether(b) NPs at various iron concentrations (n=3). 
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Figure 40. Viability of L929 cells exposed to Fe304@Si02@ineso-Si02@crowii 
ether(c) NPs at various iron concentrations (n=3). 
2.6.4 Cellular uptake of nanoparticles 
In qualitative and quantitative analyses, cellular uptake of any FesOrbased NPs can 
be determined by inductively coupled plasma-optical emission spectroscopy 
(ICP-OES), by measuring the Fe content absorbed per cell, and Prussian blue staining 
method, to identify the presence of Fe by forming insoluble and highly coloured 
complex. As shown in Figure 41, the images, which were obtained by Prussian blue 
staining method, indicated that NPs were absorbed into the L929 cell. Moreover, 
ICP-OES measurements were performed to determine the amount of Fe absorbed per 
cell and the summary of results are shown in Table 3. The amount of NPs absorbed 
5 0 
per cell was ranged from 1.7 x 10"^  to 3.3 x 10'^ |ag Fe/mL. In addition, the 
qualitative analysis of cellular uptake of NPs towards cancer cells was determined. 
HT29 cells and HepG2 carcinoma cells were studied. Unfortunately, the images 
(Figure 42-43) showed that cellular uptake of these NPs was relatively low in all 
cases for both HT29 and HepG2 cells. ICP-OES measurement was not performed 
for both NP incubated HT29 and HepG2 cell lines because large amounts of stained 
complexes located outside the cell were found in the images. It may be attributed to 
the fact that the NPs was adhered onto the surface of cell, and hence greatly 
influenced the obtained results. To our knowledge, it is believed that large NPs are 
taken up through endocytosis mechanism, but the rate and mechanism of uptake are 
cell-type dependent and vary between NPs with different size and surface 
properties.[35] Hence, it is reasonable that different uptake results are obtained 
towards different cell lines. 
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Figure 41. Cellular uptake of NPs at 5 \ig Fe/mL towards L929 cell, with Prussian 
blue stainning, a) Fe304@Si02@meso-Si02@crown ether(a), b) 
Fe304@Si02@meso-Si02@crown ether(b), c) Fe304@Si02@meso-Si02@crown 
ether(c), and d) Fe304@Si02@meso-Si02-NH2. 
Cellular uptake of 
Nanoparticle 
Fe (jag/cell) 
Fe304@Si02@meso-Si02-NH2 3.3329 xlO'^ ± 5.45 xlO'^ 
Fe304@Si02@meso-Si02@crown ether(a) 2.1472 xlO'^ 士 7.58 xlO'^ 
Fe304@Si02@meso-Si02@crown ether(b) 1.6773 xlO'^ 土 2.27 xlO"'' 
Fe304@Si02@meso-Si02@crowii ether(c) 2.2954 xlO"^ 士 1.27 xlO'^ 
Table 3. Summary of cellular uptake of NPs in L929 cell (n=3). 
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Figure 42. Cellular uptake of NPs at 5 |Lig Fe/mL towards HT29 cell, with Prussian 
blue staining, a) Fe304@Si02@meso-Si02@crown ether(a), b) 
Fe304@Si02@meso-Si02@crown ether(b), c) Fe304@Si02@meso-Si02@crown 
ether(c), and d) Fe304@Si02@meso-Si02-NH2. 
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Figure 43. Cellular uptake of NPs at 5 |ig Fe/mL towards HepG2 cell, with Prussian 
blue staining, a) Fe304@Si02@meso-Si02@crown ether(a)， b) 
Fe304@Si02@meso-Si02@crown ether(b), c) Fe304@Si02@meso-Si02@crown 
ether(c)，and d) Fe304@Si02@meso-Si02-NH2. 
2.7 Drug loading under different stimuli 
To act as a drug carrier, the drug loading capabilities of NPs under different stimuli, 
such as pH，and metal ions, are investigated and monitored by UV/Vis absorption 
spectroscopy. The drug loading processes involve the ON/OFF switching of 
nanovalves, i.e.，the open and close of the nanopores by crown ethers. Anti-cancer 
drug doxorubicin hydrochloric salt (DOX) (Figure 44) was used, which was 
monitored by the local maximum absorption wavelength at 480 nm.[36] The 
absorption spectra before and after drug loading of NPs for 24 hrs at pH 1 and pH 7 
5 4 
are shown in Figures 45 and 46. As the amount of NPs is relatively small for 
detection, diluted DOX solution (250 |ag/mL) in HCl (pH 1) or in pure H2O (pH 7) 
was used to obtain a significant absorption result. As shown in the Figures 45 and 
46, the decrease of absorption peak at 480 nm at pH 1 was smaller than that at pH 7. 
It suggests that the molecular crown ether gates is "open"/ at "ON" state at pH 7, and 
"close”/ at "OFF" state at pH 1. Table 4, shows the summary of the drug loading % 
of different NPs under two different pH conditions. It indicated that at pH 1, only 
2-9% of DOX drug molecules are loaded to the Fe304@Si02@meso-Si02@crown 
ether(a-c). That is, the nanogate of Fe304@Si02@meso-Si02@crown ether(a-c) 
IS more tightly closed in acidic medium when compared to others. In acidic 
condition, therefore, leakage of drug during the washing process will be significantly 
minimized, and the efficiency of drug storage will be higher. On the other hand, 
DOX drug loading of NPs can be facilitated at pH 7 in 31-51%. 
O OH O 
0、O 〇H O Oy, 
•HCl 
NH2 
Figure 44. Molecular structure of doxorubicin hydrochloric salt (DOX). 
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Figure 46. UV/Vis absorption spectra before and after drug loading with different NPs 
atpH 7. 
5 6 
Nanoparticle pH 7 pH 1 
Fe304 @ Si02@meso-Si02-NH2 37 土 9% 2 ± 1% 
Fe304@SiOi@meso-Si02@crwon ether(a) 55 ±6% 6 土 8% 
Fe304@Si02@meso-Si02@crwon ether(b) 43 土 0.1 % 9 ± 3% 
Fe304@Si02@meso-Si02 @crwon ether(c) 47 土 1 % 2 ± 1 % 
Table 4. Summary of percentage of drug loading for 200 |ig of different NPs at 250 
|Lig/mL ofDOX (n=2). 
After the success in loading drug molecules effectively into the NPs, a 
mechanism for closing the pores of NPs with trapped drug molecules has been 
investigated. Since dibenzo-crown ethers possess excellent supramolecular 
interactions towards metal ions, Na+ and Cs+ cations are chosen as a potential capping 
agent of the pores. Similarly, the drug loading of NPs was followed by the same 
protocol but with the use of NaCl and CsCl solutions (1 M). The UV/Vis absorption 
spectra of drug loading of NPs in the presence of different metal ions are shown in 
Figures 47-48. As shown in the spectra, the results demonstrate that the chelating 
properties of crown ether towards metal ions can be reduced significantly upon the 
drug absorption of the NPs, compared in pure H2O at pH 7. Therefore, the metal 
cations can be potentially acted as capping reagents for drug delivery system with a 
controlled release. In Table 5，it summarizes the drug loading of NPs by using 
different metal ions. Based on the least drug loading amount as 1-16%, these 
results indicate that Cs+ ions generally work more efficiently as a capping agent when 
compared to Na+ ions. However, Na+ ions work as a better capping agent of 
5 7 
Fe304@Si02@meso-Si02@crown ether(a) NPs. It may due to the preorganized 
effect of smaller interior sized dibenzo-crown ether (a) which favors stronger 
interaction for encapsulating small Na+ ions. On the other hand, larger interior sized 
dibenzo-crown ethers (b) and (c) favor stronger interaction for encapsulating larger 
Cs+ ions. Also, phosphate buffered saline (PBS) was tested for drug loading of NPs 
as it was enriched with Na+ and K+ ions. However, as shown in Table 5 and Figure 
49, the capping ability in PBS was reduced when compared to Na+ and Cs+ ions for 
different nanovalves. It may be due to the competitive binding between Na+ and K+ 
ions，leading to a dynamic effect in capping of the nanovalves. That is, the drug 
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Figure 47. UV/Vis absorption spectra before and after drug loading with different NPs 
in the presence of Cs+ ions. 
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Figure 48. UV/Vis absorption spectra before and after drug loading with different NPs 
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Figure 49. UV/Vis absorption spectra before and after drug loading with different NPs 
in PBS at pH 7.4. 
NaCl CsCl 
Nanoparticle pure H2O PBS 
(1 M) (1 M) 
Fe304@Si02@meso-Si02-NH2 31 士 9% 8 士 6o/o 2 士 3% 26 士 17o/o 
Fe304@Si02@meso-Si02@ 
51 士 60/0 18 士 12o/o 16 士 60/0 25 士 8% 
crown ether(a) 
Fe304@Si02@meso-Si02@ 
43 土 0.1% 32 士 6o/o 1 士 10/0 50 士 12% 
crown ether(b) 
Fe304@Si02@meso-Si02@ 
46 士 10/0 23±lo/o 5 土 30/0 28 士 2% 
crown ether(c) 
Table 5. Summary of percentage of drug loading for 200 \ig of different NPs at 250 
\xg/mL of DOX (n=2). 
Hence, the drug loading of NPs can be effectively performed at pH 7 in 
deionzied H2O in the absence of metal ions. Cs+ ions are effective capping agent of 
the NP's pore. In addition, drug loading efficiencies of NPs in pure H2O with 
6 0 
washing by different solutions (NaCl, CsCl or HCl) are determined. The summary 
of drug loading efficiencies after a washing treatment is shown in Table 6. It 
indicates that trapped drug molecules are released in all cases. In addition, it reveals 
that only Cs+ / Na+ are effectively capped onto the entry of the NP's pores, while 
acid-pretreated NPs show serious leakage of trapped drug molecules. It may be due 
to the protonation of unreacted amine functional group onto the surface and resulting 
in electrostatic repulsion with positively charged DOX. 
NaCl CsCl HCl 
Nanoparticle pure H2O (1 M) (1 M) (0.1 M) 
treated treated treated 
Fe304@Si02@meso-Si02-NH2 31 士 9% 31 士 0.5% 28 士 l � / � 15 士 O.io/o 
Fe304@Si02@meso-Si02@crowii ether(a) 51 士 6o/o 24 士 3o/o 21 士 S� /� 9 士 5% 
Fe304@Si02@meso-Si02@crown ether(b) 4 3 士 0.10/0 2 0 士 6 % 2 2 士 1 o/o 8 土 2 % 
Fe304@Si02@meso-Si02@crown ether(c) 46 士 l � / � 24 士 5% 23 士 3% 11 士 4% 
Table 6. Summary of drug loading efficiencies of different NPs in pure H2O with 
washing by NaCl, CsCl or HCl solutions (n=2). 
2.8 Drug release profile of nanoparticles 
To act as an ideal drug delivery system, a controlled release of drug from NPs could 
be triggered immediately by the addition of stimuli. In our nanosystem, Cs+ ions, 
and Na+ ions act as capping agent for DOX drug-loaded NPs. Also, PBS was chosen 
for controlled drug release medium in order to obtain a better mimicking nanosystem 
towards biomedical applications. For the drug release profile, the effect of capping 
agent and dibenzo-crown ethers upon pH changes and ultrasound will be studied. 
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Generally, the cancer cell environment possesses a lower pH value than normal 
tissues. The changes in pH may lead to variation of electrostatic interaction and 
hydrogen bonding, while the gain of energy form ultrasound may lead to the 
dissociation of capping agents from dibenzo-crown ethers. In addition, for the 
studies of effect of ultrasound, each data was collected from every five minutes of 
sonication and followed by three minutes of magnetic separation. In Figures 50-53, 
drug release profiles of different NPs with Cs+ capping at different .pH values are 
shown. For the cases of Fe3O4@SiO2@mes0(DOX)-SiO2@cr0wn e t h e r ( a - c ) � 
Cs+ NPs, the release profiles at pH 7.4, pH 7.4 with ultrasound, and pH 4 are similar, 
wherein only small amount of drugs were released (2-15%), while at pH 4 with 
ultrasound, the release of drug was significantly increased (24-39%). It suggests 
that the release of drug of these nanosystems can be achieved at lower pH with 
ultrasound in PBS. For the case of Fe304@Si02@mes0(D0X)-Si02-NH2 NPs 
(without crown ether), similar situations are observed, wherein only a small amount of 
drug molecules is released at pH 4，pH 7.4 and pH 7.4 with ultrasound (3-13%). 
However, a significant release of drug can be triggered at pH 4 with ultrasound (35%). . 
Without the crown ethers, the capping effect would be lowered. 
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Figure 50. Drug release profile of Fe3O4@SiO2@mes0(DOX)-SiO2-NH2 NPs with 
Cs+ capping in PBS at different conditions (monitored at 490 nm), (n=2). 
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Figure 51. Drug release profile of Fe3O4@SiO2@mes0(DOX)-SiO2@cr0wn ether(a) 
3 Cs+ NPs in PBS at different conditions (monitored at 490 nm), (n=2). 
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Figure 52. Drug release profile of Fe304@Si02@mes0(D0X)-Si02@cr0wn ether(b) 
� C s + NPs in PBS at different conditions (monitored at 490 nm), (n=2). 
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Figure 53. Drug release profile of Fe304@SiOz®mes0(DOX)"SiO2@crown ether(c) 
=> Cs+ NPs in PBS at different conditions (monitored at 490 nm), (n=2). 
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In the case of using Na+ ions as capping agent, drug release profiles of 
Fe304 @ Si02@meso(DOX)-Si02@ crown ether(a-c) ] Na+ NPs under different 
stimuli are shown in Figures 54-57. In contrast to Cs+ ion capping agent, NPs with 
or without crown ethers exhibit very similar situation upon pH changes and 
ultrasound, wherein only a small amount of drug molecules (3-9%) are released. 
Also, there is no significant increase of drug release at pH 4 compared to those with 
Cs+ ions. These results demonstrated that the 
Fe304@Si02@mes0(D0X)-Si02@cr0wn ether(a-c) ] Na+ NPs are relatively stable 
towards a low pH solution with ultrasound. 
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Figure 54. Drug release profile of Fe304@Si02@mes0(D0X)-Si02-NH2 NPs with 
Na+ capping in PBS at different conditions (monitored at 490 nm), (n=2). 
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Figure 55. Drug release profile of Fe3O4@SiO2@mes0(DOX)-SiO2@cr0wn ether(a) 
] N a + NPs in PBS at different conditions (monitored at 490 nm), (n=2). 
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Figure 56. Drug release profile of Fe304@Si02@meso(DOX)-Si02@crowii ether(b) 
] N a + NPs in PBS at different conditions (monitored at 490 nm), (n=2). 
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Figure 57. Drug release profile of Fe3O4@SiO2@mes0(DOX)-SiO2@cr0wii ether(c) 
� N a + NPs in PBS at different conditions (monitored at 490 nm), (n=2). 
2.9 MRI study of nanoparticles 
MR relaxometry of fUnctionalized NPs was performed using a clinical 1.5 T whole 
body MR system in combination with a knee radio frequency coil for excitation and 
signal reception. The MRI results of the fUnctionalized NPs are shown in Figure 56. 
A signal attenuation can be visualized at 0.3 Fe/mL, with a spin echo sequence, the 
time of repetition (TR) = 2000 ms, and time of echo (TE) = 390 ms for 
Fe304@Si02@meso-Si02-NH2, and with a spin echo sequence, TR = 2000 ms, and 
TE = 60 ms for Fe304@Si02@meso-Si02@crown ether(c). As expected for Ti 
contrast agents, the signal intensity of the MR images (Figures 58B,C) decreases 
when the Fe concentration increases. It is due to a shortening of the spin-spin 
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relaxation time of water. The graphs of spin-spin relaxation rate {Ti) as a function 
of iron concentration of functionalized NPs are shown in Figure 59. The MRI 
relaxivity ”2, which is a measure of the change in spin-spin relaxation rate (Tj^) per 
unit iron concentration, was determined as 75.3 士 5, and 235.4 士 17.2 mM~' s—! for 
Fe304@Si02@meso-Si02-NH2, and Fe304@Si02@meso-Si02@crown ether(c), 
respectively. The n relaxivity of NPs is enhanced significantly after coupling with 
dibenzo-crown ether Ic. It may be due to the coverage of dibenzo-crown ethers onto 
the surface of NPs and leading to poor dispersion and aggregation of NPs in water, 
resulting in a significant reduction of interparticle distance. Thus, the magnetic 
interaction among NPs is increased and results in enhanced MRI relaxivity r^. 
Figure 58. MRI results of functionalized NPs. A) Diagram for iron concentration 
series, B) Fe304@Si02@meso-Si02-NH2, and C) 
Fe304@Si02@meso-Si02@crown ether(c). The concentrations are 0): Deionized 
water, 1) 0.3 昭 Fe/mL, 2) 0.6 \ig Fe/mL, 3) 1.0 |xg Fe/mL, 4) 2.0 \ig Fe/mL, 5) 3.0 ^g 
Fe/mL, 6) 5.0 |xg Fe/mL. Note that image B was acquired with time-of-repetition (TR) 
of 2000 ms and time-of-echo (TE) of 390 ms. Image C was acquired with TR of 2000 
ms and TE of 60 ms. Susceptibility artifact is observed on image C at the iron 
concentration of 5.0 |xg Fe/mL. 
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Figure 59. Spin-spin relaxation rate (Zy as a function of iron concentration of 
functionalized NPs. a) Fe304@Si02@meso-Si02-NH2, and b) 
Fe304@Si02@meso-Si02@crown ether(c). Note that r^ is the relaxivity obtained 
from the slope. 
2.10 Conclusion 
A series of novel dibenzo-crown ethers la-c and novel theranostic core/shell 
Fe304@Si02@meso-Si02 NPs were successfully synthesized. Also, the 
dibenzo-crown ethers were successfully coupled onto the surface of the theranostic 
NPs, and characterized by TEM, EDX, IR and TGA. The biological study of the 
theranostic NPs was investigated and confirmed that they are biocompatible, 
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noncytotoxic towards L929 cells. In addition, cellular uptake of NPs in L929 cells 
was determined with reasonable uptake of NPs, while in HepG2 and HT29 cancer 
cells, only a small amount of NPs was absorbed. Also, the MRI relaxivity ri of NPs 
was determined as 75.3 土 5, and 235.4 士 17.2 mM"^ for 
Fe304@Si02@meso-Si02-NH2, and Fe304@Si02@meso-Si02@crown ether(c), 
respectively, by clinical 1.5 T whole body MR system. Moreover, the effect of 
stimulus towards doxorubicin drug loading was investigated. It indicated that the 
crown ether-based nanovalves on the surface of NPs could be capped by Cs+ and Na+ 
ions and possessed of different degrees of drug loading. The highest percentage of 
drug loading was found in neutral pH in the absence of metal ions. Besides, the 
release profiles of the NPs with different capping agent towards different stimulus 
were studied. The results suggested that the release of drug molecules from NPs 
with crown ether-based nanovalves with metal ion capping could be triggered by 
lowering the pH in the presence of ultrasound. In addition, the NPs without crown 
ether-based nanovalves exhibited different release mechanisms towards the changes 
in pH and ultrasound. In summary, the novel controlled release systems by the use 
of dibenzo-crown ethers as nanovalves were successfully demonstrated and found that 
the release of drug could be triggered by lowering pH in the presence of ultrasound, 
wherein it can be potentially used for biomedical applications as ultrasonic devices 
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are clinically approved and cancer cells generally provide a slightly acidic 
environment. The in vivo study of using our theranostic NPs is currently underway. 
Fe304@Si02@meso-Si02@crown ether Fe304@Si02@meso(DOX)-Si02@crown ether 
p H 4 a n d Capping 
ultrasound ^ ^ ^ ^ ^ ^ ^ ^ (Na+orCs+) 
一、^^ ^^ ^^  ^ • 
Fej04@Si02@meso-Si02(DOX)@cro�vn e t h e r � c a t i o n 
Figure 60. Schematic diagram of controlled release system of theranostic core/shell 




3.1 General Information 
Reactions were performed under nitrogen unless otherwise stated. 
Dimethylformamide was pre-dried over magnesium sulphate and distilled under 
reduced pressure. Methanol was pre-dried over CaH2 and distilled under nitrogen. 
Tetrahydrofuran was distilled from Na-benzoquinone ketal. Deionized H2O was 
obtained from Barnstead RO pure system. Chromatography purifications were 
performed on silica gel (SiO】）with the indicated eluents. All other solvents and 
reagents were of reagent grade and used as received. Preparation of NPs under 
sonication was performed by Elma Transsonic T l - H - 1 0 at 35 kHz with 80% power. 
Drug release profile with ultrasound was studied by Elma Transsonic T l - H - 1 0 at 130 
kHz with 100% power. 
^H and '^C NMR spectra for structural characterization were recorded with 
Bruker Avance 400 ('H: 400 MHz; ^^C: 101 MHz) spectrometer at 297 K. All the 
NMR samples were prepared in CDCI3 unless otherwise stated. Spectra were 
calibrated internally using the solvent residual peak (e.g., for residual CHCI3 in CDCI3, 
I 1 o 
H: (5 = 7.26; C: d = 77.16). Chemical shift were reported as parts per million (ppm) 
in d scale and coupling constants {J) were reported in hertz. Electrospray ionization 
7 2 
(ESI) mass spectra were measured on a Thermo Finnigan MAT 95XL mass 
spectrometer using CHCI3 as solvent. The reported molecular mass {m/z) values 
correspond to the most abundant monoisotopic masses. UV/Vis absorption spectra 
were obtained using a Gary 5G UV-Vis-NIR spectrophotometer. S urface analysis 
and elemental analysis of NPs were performed using a FEI TecnaiF20 field emission 
transmission electron microscope (TEM) and built-in energy-dispersive X-ray (EDX) 
spectroscopy. The iron content of NPs was determined with the iron absorption at 
238.204 nm by Optima 4300 DV inductively coupled plasma-optical emission 
spectroscopy (ICP-OES). MR relaxometry of NPs was performed using a clinical 
1.5 T whole body MR system (Siemens Sonata, Erlangen, Germany) in combination 
with a knee radio frequency coil for excitation and signal reception. 




Polyethylene glycol ditosylate, potassium carbonate and acetal 2[291 were added in 
acetone (30 mL) with stirring under nitrogen. The reaction mixture was heated 
under reflux for 2 days. The insoluble potassium salt was filtered and the filtrate 
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was concentrated under reduced pressure. The residue was purified by column 
chromatography with hexanes: EtOAc (5:1) as the eluent. 
3.2.1 Synthesis of 3a 
Triethylene glycol ditosylate (2.52 g, 5.5 mmol), potassium carbonate (2.13 g，15.4 
mmol) and acetal 2 (2.14 g, 11 mmol) were mixed. Then, the general procedure of 
synthesizing polyethers 3 was performed. The purified product was a white solid 
(1.46 g, 53%). 1 H NMR (CDCI3): 1.69 (s，12H, C(C/%), 3.84 (s, 4H, OC//2), 3.97 
(t，J = 4.9 Hz, 4H, OC//2), 4.24 (t，J = 5.2 Hz, 4H, OC//2), 6.54 (d，J = 8.2 Hz, 2H, 
Ar//), 6.63 (d, J = 8.5 Hz, 2H, Ar//), 7.40 (t，J = 8.3 Hz, 2H, AxH). ^^ C NMR 
(CDCI3): 25.8, 69.3，69.4, 71.3，103.8, 105.3, 107.0，109.5, 136.4, 157.8, 158.0, 160.9. 
HRMS (ESI): C26H30O10 [M+Na]+ calcd: 525.1731, found: 525.1726. 
3.2.2 Synthesis of 3b 
Tetraethylene glycol ditosylate (3.60 g，7.2 mmol), potassium carbonate (2.46 g, 17.8 
mmol) and acetal 2 (2.89 g, 14.9 mmol) were mixed. Then, the general procedure of 
synthesizing polyethers 3 was performed. The purified product was a yellow liquid 
(1.34 g, 35%). 1 H NMR (CDCI3): 1.68 (s, 12H，C{CH)i), 3.65-3.68 (m, 4H, OC//2), 
3.79-3.82 (m, 4H，OCHi), 3.94 (t, J = 4.9 Hz, 4H, OC//2), 4.21 (t, J=5A Hz, 4H， 
OCH2) 6.52 (d，J = 8.2 Hz, 2H, AxH), 6.62 (d, J = 8.4 Hz, 2H, MH), 7.40 (t, J = 8.4 
Hz, 2H, AxH). 13 C NMR (CDCI3): 26.2, 69.7, 69.8, 71.2, 71.7，104.2, 105.8, 107.4, 
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110.0，136.9，158.3，158.5，161.3. HRMS (ESI): C28H34O11 [M+Na]+ calcd: 
569.1993, found: 569.1999. 







Polyether 3 was added in MeOH with stirring under nitrogen. NaOMe was then 
freshly prepared by dissolving Na in dry MeOH at 0 °C, and added dropwise to the 
above mixture at 0 °C. The reaction mixture was 0 stirred at room temperature for 
24 hrs. The mixture was acidified with 0.1 M HCl until pH = 7，and concentrated by 
at reduced pressure. The residue was extracted with CHCI3 three times (50 mL x 3). 
The organic layer was collected and dried with anhydrous MgSCU. The mixture was 
filtrated and concentrated. 
3.3.1 Synthesis of 4a 
Polyether 3a (1.39 g, 2.8 mmol) was mixed in MeOH (40 mL) with stirring under 
nitrogen. NaOMe was then freshly prepared by dissolving Na (0.60 g, 26 mmol) in 
dry MeOH (20 mL) at 0 °C. Afterwards, the general procedure of synthesizing 
diester 4 was performed. The product was a pale yellow solid (1.35 g, 95%). 'H 
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NMR (CDCI3)： 3.79 (s, 4H, OC//2), 3.88-3.92 (m, 6H, COOC//3, 4H, OC//2), 4.14 (t, 
J = 5,0 Hz, 4H, OC//2), 6.39 (d, J = 8.3 Hz, 2H, AiH), 6.59 (d, J = 8.3 Hz, 2H, Ar/f), 
7.30 (t, J = 8.4 Hz, 2H, Ar/f), 11.43 (s, 2H, Ai-OH). '^C NMR (CDCI3)： 52.3, 69.1’ 
69.9, 71.3，103.6，103.7’ 110.5，135.3, 160.2，163.6’ 171.7. HRMS (ESI): C22H26O10 
[M+Na]+ calcd: 473.1418, found: 473.1416. 
3.3.2 Synthesis of 4b 
Polyether 3b (1.34 g, 2.5 mmol) was mixed in MeOH (40 mL) with 'stirring under 
nitrogen. NaOMe was then freshly prepared by dissolving Na (0.56 g, 24 mmol) in 
dry MeOH (20 mL) at 0 °C. Afterwards, the general procedure of synthesizing of 
diester 4 was performed. The product was a pale yellow solid (1.14 g, 94%). 'H 
NMR (CDCI3)： 3.66-3.70 (m, 4H, OC//2), 3.75-3.78 (m, 4H, OCH2), 3.88 (t, J = 4.6 
Hz, 4H, OCH2I 3.92 (s, 6H, COOC//3), 4.13 (t, J = 5.0 Hz, 4H, OCH2), 6.39 (d, J = 
8.3 Hz, 2H, AiH), 6.59 (d, J = 8.3 Hz, 2H, ArH), 7.30 (t, J = 8.4 Hz, 2H, AiH), 11.45 
(s, 2H, Ar-OH). '^C NMR (CDCI3)： 52.4, 69.1, 69.8, 70.9, 71.1，103.66, 103.74, 
110.5，135.2, 160.2, 163.6，171.7. HRMS (ESI): C24H3oOn [M+Na]+ calcd: 
517.1680，found: 517.1686. 
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3.4 General procedure of synthesis of dibenzo crown ether esters 5a-c 
O o , 
n 
5a: in=l, n=l 
5b: m=2, n=l 
5c: m=2. n=2 
Cesium carbonate was added in MeCN and heated under reflux with stirring under 
nitrogen. Diester 4 and polyethylene glycol ditosylate were dissolved in MeCN and 
transferred to dropping funnel. The solution was added slowly to the reaction 
mixture when it was refluxing. The reaction was carried out for 4 days and 
monitored by TLC. The reaction mixture was cooled down and concentrated. The 
insoluble salt was removed by filtration and the filtrate was dried by anhydrous 
MgSCU. The mixture was filtrated and then concentrated. The residue was purified 
by column chromatography with hexanes: EtOAc (4:1) as the eluent. 
3.4.1 Synthesis of 5a 
Cesium carbonate (9.23 g, 28.3 mmol) was dispersed in MeCN (400 mL) and heated 
under reflux with stirring under nitrogen. Diester 4a (1.58 g，3.5 mmol) and 
triethylene glycol ditosylate (1.60 g, 3.5 mmol) were dissolved in MeCN. Then, the 
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general procedure of synthesizing of dibenzo-crown ether ester 5 was performed. The 
product was a pale yellow solid (0.86 g, 43%). (H NMR (CDCI3): 3.66 (s, 8H, 
OC//2)，3.69 (s, 6H, COOC//3), 3.81 (t, J = 3.7 Hz, 8H, OC//2), 4.14 (t，J= 4.0 Hz, 
8H，OC//2), 6.49 ( d ， 8 . 4 Hz, 4H, AxH), 7.18 8.4 Hz, 2H, AxH). '^C N M R 
(CDCI3): 52.3, 69.5, 69.6, 71.2, 105.1，114.3, 130.9，156.4，167.0. HRMS (ESI): 
C28H36O12 [M+Na]+ calcd: 587.2099, found: 587.2099. 
3.4.2 Synthesis of 5b 
Cesium carbonate (6.45 g, 19.8 mmol) was added in MeCN (400 mL) and heated 
under reflux with stirring under nitrogen. Diester 4b (1.24 g, 2.5 mmol) and 
triethylene glycol ditosylate (1.15 g，2.5 mmol) were dissolved in MeCN. Then, the 
general procedure of synthesizing of dibenzo-crown ether ester 5 was performed. 
The product was a pale yellow solid (0.54 g, 35%). ^H NMR (CDCI3): 3.63-3.66 (m， 
4H, OC//2), 3.69-3.72 (m, 8H, OC//2), 3.77 (s，6H, COOC//3), 3.80-3.84 (m，8H, 
OC//2), 4 .11^ .15 (m, 8H, OC//2), 6.52 (d, J = 8.4 Hz, 4H，AxH), 111 (t,J= 8.4 Hz, 
2H，AxH), 13c NMR (CDCI3): 52.4, 69.5, 69.66，69.73, 70.8，71.4, 77.4，105.27’ 
105.29’ 114.3, 131.0, 156.5, 156.6, 167.0. HRMS (ESI): C30H40O13 [M+Na]+ calcd: 
631.2361, found: 631.2365. 
3.4.3 Synthesis of 5c 
Cesium carbonate (8.3 g, 25.4 mmol) was added in MeCN (400 mL) and heated under 
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reflux with stirring under nitrogen. Diester 4b (1.14 g, 2.3 mmol) and tetraethylene 
glycol ditosylate (1.15 g，2.3 mmol) were dissolved in MeCN. Then, the general 
procedure of synthesizing of dibenzo-crown ether ester 5 was performed. The product 
was a pale yellow solid (0.56 g, 37%). NMR (CDCI3): 3.63-3.67 (m，8H, OC//2), 
3.69-3.72 (m，8H, OC//2), 3.80-3.83 (m, 6H, COOC//3, 8H, OC//2), 4.12 (t’ J = 4.6 
Hz, 8H, 0Cif2)，6.53 (d, J = 8.4 Hz, 4H，AxH), 111 (t，J = 8.4 Hz, 2H, AvH). ^^C 
NMR (CDCI3): 52.4, 69.4, 69.7，70.8，71.3, 105.5, 114.3’ 131.1, 156.7, 166.9. 
HRMS (ESI): C32H44O14 [M+Na]+ calcd: 675.2623, found: 675.2628. 
3.5 General procedure of synthesis of dibenzo-crown ethers la-c 
O o 
n 
l a : m = l , n=l 
lb: 111=2, n=l 
Ic: ni=2, n=2 
Dibenzo crown ether esters 5 and potassium hydroxide were dissolved in MeOH/ H2O 
(1:10). The reaction mixture was stirred and refluxed under nitrogen for 24 hrs. 
The solution was acidified by 0.1 M HCl. The volatiles were removed under 
reduced pressure. The residue was extracted with CHCI3 three times (50 mL x 3). 
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The organic layer was collected and then concentrated under reduced pressure. 
3.5.1 Synthesis of la 
Dibenzo crown ether ester 5a (0.86 g, 1.5 mmol) and KOH (1.74 g, 31 mmol) were 
used. Then, the general procedure of synthesizing of dibenzo-crown ether 1 was 
performed. The product was a pale yellow solid (0.52 g，64%). NMR (CDCI3， 
two protons of COOH are missing): 3.85-3.88 (m，16H，OC//2), 4.16 (t, J = 4.2 Hz, 
8H，OC//2), 6.59 (d, J = 8.4 Hz, 4H, AiH), 7.28 (m, 2H, AxH). " C.NMR (CDCI3): 
69.6，70.6, 70.8, 107.0，115.9，131.3, 156.4，173.2. HRMS (ESI): C26H32O12 
[M+Na]+ calcd: 559.1786, found: 559.1786. 
3.5.2 Synthesis of l b 
Dibenzo crown ether ester 5b (0.42 g, 0.65 mmol) and KOH (0.77 g，13.8 mmol) 
were used. Then, the general procedure of synthesizing of dibenzo-crown ether 1 
was performed. The product was a pale yellow solid (0.31 g, 76%). 'H NMR 
(CDCI3，two protons of COO//are missing): 3.75-3.77 (m, 4H, OC//2), 3.82-3.84 (m, 
4H, OCH2) 3.88-3.92 (m，12H, OC//2), 4.15-4.19 (m, 8H, OC//2), 6.55 (d，J= 8.4 Hz, 
4H, Ar/f), 7.25—7.27 (m, 2H, AxH). '^C NMR (CDCI3): 68.6，69.3, 69.6，70.1, 70.4, 
70.5，71.4，105.2, 105.3, 113.8, 131.4, 156.4, 156.5, 172.3. HRMS (ESI): C28H36O13 
[M+Na]+ calcd: 603.2048，found: 603.2038. 
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3.5.3 Synthesis of Ic 
Dibenzo crown ether 5c (0.37 g，0.59 mmol) and KOH (0.68 g, 12.1 mmol) were used. 
Then, the general procedure of synthesizing of dibenzo-crown ether 1 was performed. 
The product was a pale yellow solid (0.25 g, 71%). 'H NMR (CDCI3, two protons of 
COO//are missing): 3.73-3.76 (m, 8H, OCH2), 3.78-3.80 (m, 8H, OC//2), 3.89 (t，J 
=4.0 Hz, 8H, OC//2), 4.18 (t, 4.2 Hz, 8H, OC//2), 6.55 (d, J = 8.4 Hz, 4H, AiH), 
7.26—7.31 (m，2H, ArH). '^C NMR (CDCI3): 69.4, 70.7，71.9, 105.1，113.0, 131.7, 
157.1，171.8. HRMS (ESI): C30H40O14 [M+Na]+ calcd: 647.2310，found: 647.2311. 
3.6 Preparation of superparamagnetic FesO* nanoparticle with an average 
diameter 120 n m _ 
FeCl3.6H20 (0.54g, 2 mmol) and polyacrylic acid (53.5 mg) were dissolved in 
ethylene glycol and diethylene glycol (4.5:15.5) with a total volume 20 mL under 
magnetic stirring. NaOAc (1.50 g) was added into the mixture. The reaction 
mixture was stirred for 30 min until the NaOAc was completely dissolved. The 
obtained homogeneous green solution was transferred to a Teflon-lined stainless-steel 
autoclave and sealed to heat at 200 °C. After reaction for 12 hrs, the autoclave was 
cooled to room temperature. The obtained FejOi NPs were washed several times 
with deionized H2O, and then dispersed into 15 mL deionized H2O. 
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3.7 Preparation of core/shell Fe304@Si02 nanoparticle^^ 
An aqueous solution (2.5 mL) of Fe304 NPs was diluted with deionzied water (0.5 
mL) and EtOH (30 mL) under ultrasonication. Ammonia solution (1 mL) was added. 
After ultrasonication for 2.5 hrs, a solution of tetraethyl orthosilicate (TEOS) in EtOH 
(40 (jL of TEOS in 5 mL of ethanol) was injected into the solution in five portions. 
The reaction was performed for 80 min and the product was collected by the help of a 
magnet. The Fe304@Si02 NPs were washed with EtOH and deionized H2O for 
several times and then dispersed in deionized H2O (50 mL). 
3.8 Preparation of Fe304@Si02@meso(CTAB)-Si02 nanoparticle 
Poly(vinylpyrrolidone) (PVP) (1 g) was dissolved in prepared Fe304@Si02 solution 
(50 mL) under ultrasonication for 5 hrs. The NPs were collected by the help of 
magnet and redispersed into deionzied H2O (100 mL). Cetyl trimethylammonium 
bromide (CTAB) (0.77 g) was added into the solution. The mixture was 
homogenized by ultrasonication for 2 hrs. Afterwards, TEOS (0.15 mL) was 
injected into the solution and the mixture was sonicated for another 2 hrs. Ammonia 
solution (3 mL) and EtOAc (9 mL) were injected into the mixture. After 1 hrs for 
reaction, TEOS (5 |aL X 3) was injected into the solution. The reaction was 
performed for 120 min and the NPs were collected by the help of magnet and then 
washed with EtOH for twice. In addition, Fe304@Si02@meso(CTAB)-Si02 NPs 
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could be heated under reflux in acetone, or heated at 60 ° C in EtOH, to remove 
surfactant (CTAB)，and gave Fe304@Si02@meso-Si02 NPs. 
3.9 Preparation of Fe304@Si02@meso(CTAB)-Si02-NH2 nanoparticle 
Fe304@Si02@meso(CTAB)-Si02 NPs were dispersed into EtOH (50 mL). The 
solution was homogenized by ultrasonication for 1 hr. 
3-AminopropyItriethoxysilane (APTES) (1 mL) was injected into the solution and the 
mixture was sonicated for 1 hr. The reaction was performed under mechanical 
stirring for 24 hrs at room temperature. The product was collected by the help of 
magnet, and then washed with EtOH and H2O for several times, to remove unreacted 
APTES. Finally, the product was dried under reduced pressure for 12 hrs to obtain 
core/shell Fe304@Si02@meso(CTAB)-Si02-NH2 NPs. In addition, 
Fe304@Si02@meso(CTAB)-Si02-NH2 NPs could be washed with DMF, to remove 
surfactant (CTAB), and gave Fe304@Si02@meso-Si02-NH2 NPs. 
3.10 Preparation of Fe304@Si02@meso-Si02@crown ether(a-c) nanoparticles 
The dried Fe304@Si02@meso(CTAB)-Si02-NH2 NPs (30 mg) were dispersed in dry 
DMF (50 mL) under nitrogen. A^-Hydroxysuccinimide (NHS) (44.8 mg), 
dibenzo-crown ethers la/b/c and N,A^'-dicyclohexyIcarbodiimide (DCC) (79.1 mg) 
were dissolved in dry DMF (30 mL), and then added into the solution slowly under 
ultrasonication. After an hour, the reaction was performed under magnetic stirring 
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under nitrogen at 30 °C for 48 hrs. The product was collected by the help of magnet 
and then washed with DMF, ethanol and water successively for several times, to 
remove excess dibenzo-crown ethers, NHS, DCC and surfactant (CTAB). Finally, 
the product was dried under reduced pressure for 12 hrs to obtain desired 
Fe304@Si02@meso-Si02@crown ethers(a-c) NPs. 
3.11 Protocol of biological study of functionalized nanoparticles 
3.11.1 MTT protocol 
10 i^ L of MTT solution (5 mg/mL) was added to each well. Aft er 4 hrs incubation, 
the medium was removed and formazan crystals were dissolved with 150 |iL DMSO 
for 10 min on a shaker. The absorbance of each well was measured by a microplate 
reader at a wavelength of 540 nm. The relative cell viability (%) for each sample 
related to control well was calculated. 
3.11.2 Cytotoxicity study 
10,000 of L929 cells were seeded into the wells from the 96-well plates. After 12 
hrs incubation, the medium in the wells was replaced with 90 |iL DMEM (10% FBS)， 
and 10 \iL serial dilutions of NPs were added with final iron concentrations from 6.25 
to 100 fig Fe/mL. After 24 hrs incubation, the MTT protocol of cytotoxicity study was 
performed. 
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3.11.3 Cell adhesion study 
10,000 of L929 cells were seeded into each well of a 96-well plate. After 12 hrs 
incubation, the medium in the wells was replaced with 90 \iL DMEM (10% FBS for 
L929), and 10 |xL serial dilutions of NPs were added with final iron concentrations 
from 6.25 to 100 |ig Fe/mL. After 4 hrs incubation, the MTT protocol of 
cytotoxicity study was performed. 
3.11.4 Cell proliferation study 
5,000 of L929 cells were seeded into each well of a 96-well plate. After 12 hrs 
incubation, the medium in the wells was replaced with 90 |jL DMEM (10% FBS for 
L929), and 10 |iL serial dilutions of NPs were added with final iron concentrations 
from 6.25 to 100 |xg Fe/mL. After 24, 48’ or 72 hrs incubation, the MTT protocol of 
was performed respectively. 
3.11.5 Cellular uptake of functionalized nanoparticles 
The cellular uptake of Fe304@Si02@meso-Si02-NH2 and 
Fe304 @ Si02@meso-Si02@ crown ether(a-c) NPs were evaluated in L929, HepG2 
and HT29 cells by Prussian blue staining. In additions, intracellular iron 
concentration study of L929 was evaluated by ICP-OES. The cells were seeded in a 
24-well plate in DMEM medium containing 10% FBS. After 12 hrs incubation, 
medium was replaced with serum-free DMEM medium containing NPs with the 
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concentration of 5 |ag Fe/mL and incubated for another 20 hrs. At the end of 
incubation, cells were washed with PBS for 3 times, and Prussian blue staining or 
ICP-OES analysis was performed. In Prussian blue staining, cells were fixed for 40 
min by using 4% paraformaldehyde. After washing with PBS, the cells were 
incubated wkh Perls' reagent (4% potassium ferrocyanide and 6% HCl) for 30 min, 
and followed by a neutral red counterstain. The cells were observed using a light 
microscopy. To determine intracellular iron concentration, the cells were collected 
and counted. Cells were resuspended in 200 |jL 12% HCl solution and incubated at 
60 °C for 4 hrs to dissolve NPs. Few drops of concentrated aqueous SnCli were 
added, and the solution was further diluted to 1 mL. Subsequently ICP-OES was 
performed to study the iron concentration, 
3.12 Drug loading of functionalized nanoparticles 
200 |XL of NP solution (1 mg/mL)，100 |iL of DOX solutions (1 mg/mL) and 100 i^L 
of stimuli (1 M NaCl / 1 M CsCl /PBS / 0.1 M HCl / deionized H2O) were mixed. 
The drug loading was performed for 24 hrs. Then, magnetic NPs were separated 
under the help of magnet and 200 \iL of mixture was withdrawn for the UV/Visible 
absorption spectroscopic measurement (from 200 nm to 800 nm), such that the drug 
loading efficiency under different stimulus can be evaluated. • 
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3.13 Drug release profile of functionalized nanoparticles 
1 mL of NP solution (1 mg/mL) was loaded wkh 0.5 mL of DOX (2 mg/mL) in 
deionized H2O. The loading efficiency was determined by UV/Visible absorption 
spectroscopy. The pore entry of NPs was blocked by addition of 500 |J,L of capping 
agent (0.1 M HCl/ 1 M CsCl/ 1 M NaCl) and followed by washing with capping agent 
three times (500 )xL x 3). The loading efficiency of NPs after washing was then 
determined by separation of NPs wkh the help of magnet. The release profile of NPs 
was performed in PBS (at different pH) and monitored by UV/Visible absorption 
spectroscopy. For drug release studies with ultrasound, each data was collected by 
sonication of NPs for 5 min, and followed by 3 min of separation under magnetic 
field. 
3.14 MRI study of nanoparticles 
Two NPs samples were dispersed in deionized H2O at iron concentrations in a range 
from 0.3 to 5 |xg Fe/mL. For MR measurements, dispersed NPs solutions at different 
concentrations were filled in each Eppendorf tube (1.5 mL). Sonication was applied 
for 10 min prior to MRI. T2 relaxation times were measured using a standard 
Carr-Purcell-Meiboom-Gill pulse sequence [time of repetition (TR) = 2000 ms, time 
of echo (TE) range = 30-960 ms, 32 echoes, field of view (FOV) = 134 x 67 _ 2， . 
matrix = 128 x 64, slice thickness = 5 mm, NEX = 3], T2 relaxation times were 
8 7 
calculated by a linear fit of the logarithmic ROI signal amplitudes versus TE. The 
relaxivities {ri) were determined by a linear fit of the inverse relaxation times as a 
function of the iron concentrations used. 
8 8 
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1. NMR spectrum of dibenzo-crown ether la in CDCI3 
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3. H^ NMR spectrum of dibenzo-crown ether lb in CDCI3 
丨丨I 




a / • /Z6-£ 
i - • 
‘ ： 对 £8'“ 
/ — — ； Cgs-z 
[ 
• ： ； 
一 in 
V 
-i \ ：  •“ \ ；; 
：：^ ‘ <00>' 
‘ ’ , • • ‘ ••• / 、 
； ；…卜 
y. ；; C： ‘ ,： ‘.、 • 
• i：；, “ ‘ ； — - _ • 二 / . ‘ 
；v^.；. / ； r � 
. > 
•…CO 
r 夕 。 ^ 
> - ： 
r 
A5 









MLZ-m-^- • ^ 
cus m • 
gOSO O^  •V：^^ - ……….).…J •； o 
Di Ot'Oi 一 •=： -rr^-r-r^rrT^ 卜 謂 "y .. i � 





^ � S C l ' . � J 
ezss'^ jci o 
cgig-gii 一 、 ： 
- o <Ni 
' . . o 
、 3 ^ 




卜 z , ^ O 
.. i： 
, f O , (••"卜 
esie'sa— 一一”"一一一.....-[广 
J ^ � 
> “ 八 J � i， 
C 1 丨 ； 




4. 13c NMR spectrum of dibenzo-crown ether lb in CDCI3 
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10. 13c NMR spectrum of polyether 3b in CDCI3 
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9. 1h NMR spectrum of polyether 3b in CDCI3 
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11. 1h NMR spectrum of diester 4a in CDCI3 
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20. 13c NMR spectrum of dibenzo-crown ether ester 5c in CDCI3 
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20. 13c NMR spectrum of dibenzo-crown ether ester 5c in CDCI3 
r E a a 
t 
贩 0‘e _ -
I : 
u..trt‘.\ ’ I OOtSt't^  丨 f j 'r- <0 
fit&s-c-^l I [ 
i i 
z z : : ^ r 
s ? ? :喻 — i 丨 < 1 ^ 
-u) f f 
• i-
I 
V < r 
f r- <0 f ； 
t!m‘，〜、 [ ^ � I rc^ JO^ L. 
f 
TEOK't. -V. 广 
^ 
( 3 m ‘ i ~ ^ z 
[ I 
- CO 
1 J L 
广〉） O^OMc .(/ ( ) h 
Z o OMC 0 � 
u • 
A21 
20. 13c NMR spectrum of dibenzo-crown ether ester 5c in CDCI3 
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